Psychedelic Therapeutics Market Size is valued at USD 2.2 Billion in 2024 and is predicted to reach USD 9.6 Billion by the year 2034 at a 15.6 % CAGR during the forecast period for 2025-2034.
Psychedelic medicines are also referred to as hallucinogenic. Psychedelic medicines are a group of substances, including chemicals, such as LSD, and plants used to treat multiple mental disorders, including resistant depression, opiate addiction, and panic disorder, among others. This medicine changes and enhances sensory perceptions, thought processes, and energy levels and facilitates favorable experiences.
The Global psychedelic therapeutics market is proliferating owing to the increasing incidence of depression cases across the world. Additionally, changed lifestyles and quality of living are supporting the growth of psychedelic medicine market. In addition, the market is anticipated to expand lucratively as a result of the growing need for medicines to treat psychological drug dependency. On the other hand, a greater acceptance of non-therapeutic treatments over allopathic therapies and tight rules implemented by various governments to commercialize psychedelic medications may inhibit the market growth.
In 2023, North America led the market. Major determinants, such as the increase in the frequency of depression and other mental diseases and the rapid advancement of research, are driving the market growth. The population's increased awareness of anxiety and mental health is anticipated to stimulate regional growth further. The Asia-Pacific region is anticipated to see a considerable growth rate over the projected period as a result of the growing awareness of mental diseases and the expansion of healthcare infrastructure.
The global psychedelic therapeutics market is segmented on the basis of Origin of Psychedelic Substance, Type of Psychedelic Substance, Target Therapeutic Area and region. Based on the Origin of Psychedelic Substance, the market is divided into Synthetic Substances and Natural Substances. On the basis of Type of Psychedelic Substance, the market is divided in to GHB, Ketamine, MDMA and Psilocybin.
On the basis of Target Therapeutic Area, the market is divided into Depression and Anxiety Disorders, Pain Disorders, Sleep-Related Disorders and Trauma. Based on region, the market is studied across North America, Asia-Pacific, Europe, and LAMEA. Among that Europe held the largest share of the market, followed by America and Asia Pacific. On the other hand, North America is expected to dominate the market during the analysis of forecast period.
| Report Attribute | Specifications |
| Market Size Value In 2024 | USD 2.2 Billion |
| Revenue Forecast In 2034 | USD 9.6 Billion |
| Growth Rate CAGR | CAGR of 15.6 % from 2025 to 2034 |
| Quantitative Units | Representation of revenue in US$ Billion and CAGR from 2025 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2025-2034 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | Type of Psychedelic Substance, Origin of Psychedelic Substance, Target Therapeutic Area |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
| Competitive Landscape | Celon Pharma S.A., MAPS Public Benefit, MindMed, Janssen Pharmaceuticals, iX Biopharma Ltd, Jazz Pharmaceutical, Avadel, Pharmaceuticals plc, NeuroRx, Inc., Douglas Pharmaceuticals Limited, The Emmes, Company, LLC, CaaMTech, COMPASS Pathways plc, Eleusis Benefit Corporation, AWAKN Life Sciences Inc, Psilera Bioscience, Braxia Scientific Corp., Mindset Pharma, BetterLife Pharma, Cybin, CB Therapeutics, Numinus Wellness, Mydecine Innovations Group, Optimi Health, PharmaTher, Field Trip Health, ATAI Life Sciences, GH Research, Seelos Therapeutics, Small Pharma, Bright Minds Biosciences, Incannex Health, PsyBio Therapeutics, Universal Ibogaine, Levitee Labs, Mind Cure Health, Novamind, Clearmind Medicine, MYND Life Science, Wesana Health, Psyched Wellness, HAVN Life Sciences, Tryp Therapeutics, Psyence Group, Silo Pharma, Core One Labs, M2Bio Sciences, Neonmind Biosciences, Delic Corp, Nova Mentis Life Science, Beckley Psytech, Delix Therapeutics, Diamond Therapeutics, Tactogen, Psygen Labs Inc., Bexson Biomedical, Eleusis Biotech, Psilera Biosceince, Octarine Bio, Heading Health, MAPS Public Benefit Corporation (PBC), Aphrodite Health, Terran Biosciences, Mycrodose Therapeutics, Reset Pharma, Clerkenwell Health, Alvarius Pharmaceuticals, Ceruvia Lifesciences, and Other Prominent Player. |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Psychedelic Therapeutics Market- By Origin of Substance
Psychedelic Therapeutics Market- By Type of Psychedelic Substance
Psychedelic Therapeutics Market- By Target Disease Indications
Psychedelic Therapeutics Market- By Route of Administration
Global Psychedelic Therapeutics Market Revenue (US$ Mn) Based on Region
Europe Psychedelic Therapeutics Market Revenue (US$ Mn) by Country
North America Psychedelic Therapeutics Market Revenue (US$ Mn) by Country
Asia Pacific Psychedelic Therapeutics Market Revenue (US$ Mn) by Country
Latin America Psychedelic Therapeutics Market Revenue (US$ Mn) by Country
Middle East & Africa Psychedelic Therapeutics Market Revenue (US$ Mn) by Country
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.